Management of AKI in Cirrhosis by Salvatore Piano, MD (Padova, Italy)

Comprehensive Summary: Management of AKI in Cirrhosis

Speaker: Dr. Salvatore Piano, MD — Associate Professor of Medicine & Consultant Hepatologist, University Hospital of Padova, Italy

1. Main Clinical Topics Discussed

• Epidemiology and pathophysiology of acute kidney injury (AKI) in cirrhosis
• Diagnostic criteria and staging of AKI in cirrhotic patients
• Evidence-based management algorithms (EASL/International Club of Ascites guidelines)
• Hepatorenal syndrome (HRS-AKI): diagnosis, differentiation, and treatment
• Pharmacological rationale for vasoconstrictors (terlipressin) and albumin
• Controversial issues and future management strategies

2. Key Learning Points, Guidelines, and Recommendations

Pathophysiology

• Portal hypertension → increased gut bacterial translocation → systemic inflammation → splanchnic arterial vasodilation (mediated by nitric oxide, carbon monoxide) → reduced effective circulating volume
• Compensatory activation of vasoconstrictors (catecholamines, renin-angiotensin-aldosterone system) initially maintains cardiac output but ultimately contributes to renal vasoconstriction
• Additional AKI mechanisms include: oxidative stress from systemic inflammation (direct renal tubular injury), cholemic nephropathy from bile acid accumulation, and elevated intra-abdominal pressure in tense ascites
• Precipitating factors identified in >90% of cases if systematically sought; most common are bacterial infections and volume loss

AKI Staging (KDIGO-based criteria applied to cirrhosis)

• Diagnostic criteria: ↑ serum creatinine ≥0.3 mg/dL within 48 hours, OR ≥50% relative increase within 7 days, OR urine output <0.5 mL/kg/hr for >6 hours
• Stage 1: <2-fold increase from baseline

- Stage 1A: Creatinine <1.5 mg/dL (better prognosis)

- Stage 1B: Creatinine ≥1.5 mg/dL (worse prognosis)

• Stage 2: 2- to 3-fold increase
• Stage 3: >3-fold increase, OR creatinine ≥4 mg/dL, OR requirement for renal replacement therapy

EASL Management Algorithm

• AKI Stage 1A: Close monitoring; identify/remove precipitating factors; taper/withdraw diuretics; plasma volume expansion as indicated; treat infections
• AKI Stage ≥1B: Diuretic withdrawal + albumin 1 g/kg body weight/day for 2 days; reassess for HRS criteria if no improvement
• If HRS criteria not met → treat specific phenotype (most commonly acute tubular necrosis — supportive management; rarely IgA nephropathy or glomerulonephritis)
• If HRS criteria met → vasoconstrictors + albumin

HRS-AKI Diagnostic Criteria (International Club of Ascites)

• Cirrhosis with ascites
• No improvement in creatinine after ≥2 days of diuretic withdrawal + albumin volume expansion
• Absence of shock
• No recent nephrotoxic drug use
• No signs of parenchymal kidney disease (no significant proteinuria, microhematuria, or abnormal renal ultrasound)

Treatment of HRS-AKI

• First-line: Terlipressin + albumin
• Second-line (where terlipressin unavailable/unaffordable): Noradrenaline + albumin
• Third-line (limited indications): Midodrine + octreotide + albumin
• Pharmacokinetic note: Terlipressin given as IV boluses every 4–6 hours fails to maintain hemodynamic effect across the full 24-hour period (effect duration ~3 hours per dose), representing a pharmacodynamic limitation of current dosing practice

3. Specific Clinical Data and Study Results Cited

• ~50% of hospitalized decompensated cirrhosis patients develop AKI during admission
• AKI in cirrhosis is associated with a **